Release time:2017-11-02 16:00:00

Irinotecan (API)
This product is the main component of irinotecan hydrochloride. The chemical name is (+) - (4S) -4,11-diethyl-4-hydroxy-9 - [(4-piperidinylpiperidine) carbonyl] -1H-pyrano [3,4: 6 , 7] indolizine [1,2b] quinoline-3,14- (4H, 12H) -dione hydrochloride trihydrate. English name: Irinotecan

CAS: 100286-90-6
Molecular formula: C33H38N4O6 • HCl
Molecular weight: 623.14
Melting point: 250-256 ° C

       White or light yellow powder, soluble in water, methanol; slightly soluble in chloroform, ethanol; almost insoluble in acetone, ether. Efficacy: irinotecan has different effects on lung cancer (small cell lung cancer, non-small cell lung cancer), colon cancer, rectal cancer, ovarian cancer, cervical cancer, gastric cancer, lymphoma, breast cancer, leukemia, etc. Small cell lung cancer and colon cancer efficacy, more than the current anti-cancer drug activity.

       Irinotecan product quality in line with US USP standards, specifications are as follows:

Product Usage
       Irinotecan hydrochloride irinotecan. The chemical name is (+) - (4S) -4,11-diethyl-4-hydroxy-9 - [(4-piperidinylpiperidine) carbonyl] -1H-pyrano [3,4: 6 , 7] indolizine [1,2b] quinoline-3,14- (4H, 12H) -dione hydrochloride trihydrate. Irinotecan is a semi-synthetic derivative of camptothecin. Camptothecin can react specifically with topoisomerase I, which induces reversible single strand breaks to render DNA double-stranded structures spin off; irinotecan and its active metabolite SN-38 can bind to topoisomerase I-DNA complex binding, thereby preventing the cleavage of single stranded ligation. Mainly for the treatment of patients with advanced colorectal cancer. Combined with 5-fluorouracil and leucovorin in patients with advanced colorectal cancer who had not previously received chemotherapy as a single medication to treat patients who had failed treatment with 5-fluorouracil chemotherapy regimen.

National policy
       Irinotecan for the treatment of adult metastatic colorectal cancer, with 5-Fu chemotherapy failure in patients with this product can be used as second-line treatment. At the same time, irinotecan used in gastric cancer, esophageal cancer, extensive small cell lung cancer in a variety of clinical trials are ongoing, the results have been drawn from the observation point of view, there is a good clinical prospects.

Product advantages
       The use of fully synthetic 7-ethyl-10-hydroxycamptothecin production of irinotecan has entered the US Pharmacopoeia, its quality indicators are far higher than the current market of semi-synthetic camptothecin products, our company's quality indicators: Purity ≥ 99.5%, single impurity ≤ 0.1%; other semi-synthetic hydroxycamptothecin quality index for the purity of ≥ 99%, a single impurity ≤ 0.3%. The semi-synthetic products, the current process conditions simply can not do the product to the quality of synthetic products standards, therefore, fully synthetic hydroxyl products into the market after the quality of the price of more than semi-synthetic products, has a certain competitive advantage.
       The company and the Shanghai Fudan University, Wuhan University of Science and Technology and Jing Chu College of Technology to establish long-term cooperation mechanism, make full use of the technical advantages of colleges and universities, production, learning, research integration of the road, joint research and development of new drugs and product improvement, Reserve generation, research and development of the road, so that products always walk in the forefront of market demand. In April 2016, the company and the Chinese Academy of Engineering, Fudan University Professor Chen Fener to establish "academician workstation", in the future, the academician team of experts will be the development of enterprises to provide the most favorable technical support. The company has now made 14 patented technology, and two patents have entered the trial stage of the invention.